Forest Settles With Spitzer; Trial Registry Will Focus On Phase III-IV
Executive Summary
Forest Labs' settlement agreement with New York Attorney General Eliot Spitzer requires less disclosure of clinical data than an earlier settlement between Spitzer and GlaxoSmithKline
You may also be interested in...
Negative Antidepressant Trial Results See Low Publication Rate, Study Finds
The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine
Negative Antidepressant Trial Results See Low Publication Rate, Study Finds
The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine
Access To Vaccine Safety Data Is Different Than Trial Databases, NVAC Says
The Institute of Medicine's proposal to open the Vaccine Safety Database to independent research is "very different" than granting public access to registries of clinical trials, the National Vaccines Advisory Committee said